What cautions should guide the use of cannabinoids in symptom management?

Study for ELNEC 4: Symptom Management in Palliative Care Test with flashcards and multiple choice questions. Hints and explanations included! Get ready for your exam!

Multiple Choice

What cautions should guide the use of cannabinoids in symptom management?

Use of cannabinoids in symptom management requires mindful consideration of legal status, potential cognitive effects, and possible drug interactions, with cautious, monitored use. Cannabinoids can offer relief for symptoms like nausea, appetite loss, pain, and spasticity, which is why they’re considered in palliative care. But they can also cause cognitive effects such as impaired memory, slower reaction time, dizziness, and mood changes, which can be especially challenging for older patients or those with preexisting psychiatric conditions. Because the legal landscape varies widely, it’s essential to confirm local laws and institutional policies, obtain appropriate authorization when required, and document consent and rationale. Interactions with other medications are a real consideration—cannabinoids can affect liver enzymes and alter the metabolism of other drugs, potentially increasing or decreasing their effects, and they can intensify sedation when used with other CNS depressants. Given these factors, use should be cautious: start low, go slow, monitor closely for benefits and adverse effects, tailor the route and formulation to the patient’s needs and goals, and ensure ongoing compliance with legal and policy requirements.

Use of cannabinoids in symptom management requires mindful consideration of legal status, potential cognitive effects, and possible drug interactions, with cautious, monitored use.

Cannabinoids can offer relief for symptoms like nausea, appetite loss, pain, and spasticity, which is why they’re considered in palliative care. But they can also cause cognitive effects such as impaired memory, slower reaction time, dizziness, and mood changes, which can be especially challenging for older patients or those with preexisting psychiatric conditions. Because the legal landscape varies widely, it’s essential to confirm local laws and institutional policies, obtain appropriate authorization when required, and document consent and rationale. Interactions with other medications are a real consideration—cannabinoids can affect liver enzymes and alter the metabolism of other drugs, potentially increasing or decreasing their effects, and they can intensify sedation when used with other CNS depressants. Given these factors, use should be cautious: start low, go slow, monitor closely for benefits and adverse effects, tailor the route and formulation to the patient’s needs and goals, and ensure ongoing compliance with legal and policy requirements.

More practice questions